Chardan Capital Forecasts Metagenomi FY2025 Earnings

Metagenomi, Inc. (NASDAQ:MGX) – Research analysts at Chardan Capital issued their FY2025 earnings per share estimates for shares of Metagenomi in a report released on Monday, March 24th. Chardan Capital analyst G. Livshits anticipates that the company will post earnings of ($1.47) per share for the year. The consensus estimate for Metagenomi’s current full-year earnings is ($2.46) per share. Chardan Capital also issued estimates for Metagenomi’s FY2026 earnings at ($0.76) EPS.

A number of other equities analysts have also recently weighed in on MGX. Wells Fargo & Company lowered their price target on Metagenomi from $25.00 to $20.00 and set an “overweight” rating for the company in a report on Tuesday, March 18th. HC Wainwright increased their target price on shares of Metagenomi from $7.00 to $14.00 and gave the stock a “buy” rating in a research note on Tuesday, December 10th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $14.40.

Metagenomi Stock Performance

Shares of Metagenomi stock opened at $1.54 on Thursday. The stock has a 50 day moving average of $2.27 and a 200 day moving average of $2.45. The firm has a market capitalization of $57.57 million and a price-to-earnings ratio of -0.59. Metagenomi has a fifty-two week low of $1.53 and a fifty-two week high of $11.13.

Metagenomi (NASDAQ:MGX) last posted its quarterly earnings results on Monday, March 17th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.01). The firm had revenue of $9.61 million during the quarter, compared to analysts’ expectations of $13.18 million. Metagenomi had a negative net margin of 134.27% and a negative return on equity of 43.23%. During the same period last year, the company earned ($20.05) EPS.

Hedge Funds Weigh In On Metagenomi

Several institutional investors have recently bought and sold shares of the company. Norges Bank acquired a new position in shares of Metagenomi in the fourth quarter worth $1,300,000. Peapod Lane Capital LLC acquired a new position in Metagenomi during the 4th quarter worth $1,268,000. Geode Capital Management LLC increased its holdings in Metagenomi by 73.8% during the 4th quarter. Geode Capital Management LLC now owns 587,421 shares of the company’s stock worth $2,121,000 after purchasing an additional 249,390 shares during the period. Northern Trust Corp raised its position in Metagenomi by 185.6% in the 4th quarter. Northern Trust Corp now owns 223,934 shares of the company’s stock valued at $808,000 after purchasing an additional 145,536 shares in the last quarter. Finally, Good Life Advisors LLC purchased a new position in shares of Metagenomi in the 4th quarter valued at about $451,000.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.